In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-22 of 22 for your search:
Drug:  crizotinib
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Health services research, Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Q-CROC-05, NCT02041468

2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: A8081029, NCT01639001

3.

Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO28984, NCT02075840

4.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL0912, COG-ADVL0912, CDR0000647587, NCT00939770

5.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-015, NCT01579994

6.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AT13387-05, 2012-001575-37, NCT01712217

7.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A8081005, NCT00932451

8.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: EORTC-90101, 2011-001988-52, NCT01524926

9.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00737, RTOG 1306, U10CA021661, NCT01822496

10.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OO 12-01, NCT01945021

11.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2013-02167, COG-ANHL12P1, ANHL12P1, U10CA098543, NCT01979536

12.

Phase: Phase II
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: UC-0105/1303, 2013-000885-13, NCT02034981

13.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BRE12-158, NCT02101385

14.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A8081001, NCT00585195

15.

Phase: Phase I
Type: Treatment
Status: Active
Age: not specified
Sponsor: Other
Protocol IDs: 2011-1142, NCT01548144

16.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A8081012, NCT01576406

17.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 months to 21 years
Sponsor: NCI, Other
Protocol IDs: ADVL1212, NCI-2012-01968, U01CA097452, COG-ADVL1212, NCT01606878

18.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: SJHG12, NCT01644773

19.

Phase: Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 2012-0721, NCT01744652

20.

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HCI66705, NCT01998126

21.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4061068, NCT01999972

22.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: H-33624, NCT02074878
New Search